Cartilage protective and anti-analgesic effects of ALM16 on monosodium iodoacetate induced osteoarthritis in rats

BMC Complement Altern Med. 2019 Nov 21;19(1):325. doi: 10.1186/s12906-019-2746-7.

Abstract

Background: Osteoarthritis (OA) is an age-related joint disease with characteristics that involve the progressive degradation of articular cartilage and resulting chronic pain. Previously, we reported that Astragalus membranaceus and Lithospermum erythrorhizon showed significant anti-inflammatory and anti-osteoarthritis activities. The objective of this study was to examine the protective effects of ALM16, a new herbal mixture (7:3) of ethanol extracts of A. membranaceus and L. erythrorhizon, against OA in in vitro and in vivo models.

Methods: The levels of matrix metalloproteinase (MMP)-1, -3 and - 13 and glycosaminoglycan (GAG) in interleukin (IL)-1β or ALM16 treated SW1353 cells were determined using an enzyme-linked immunosorbent and quantitative kit, respectively. In vivo, the anti-analgesic and anti-inflammatory activities of ALM16 were assessed via the acetic acid-induced writhing response and in a carrageenan-induced paw edema model in ICR mice, respectively. In addition, the chondroprotective effects of ALM16 were analyzed using a single-intra-articular injection of monosodium iodoacetate (MIA) in the right knee joint of Wister/ST rat. All samples were orally administered daily for 2 weeks starting 1 week after the MIA injection. The paw withdrawal threshold (PWT) in MIA-injected rats was measured by the von Frey test using the up-down method. Histopathological changes of the cartilage in OA rats were analyzed by hematoxylin and eosin (H&E) staining.

Results: ALM16 remarkably reduced the GAG degradation and MMP levels in IL-1β treated SW1353 cells. ALM16 markedly decreased the thickness of the paw edema and writhing response in a dose-dependent manner in mice. In the MIA-induced OA rat model, ALM16 significantly reduced the PWT compared to the control group. In particular, from histological observations, ALM16 showed clear improvement of OA lesions, such as the loss of necrotic chondrocytes and cartilage erosion of more than 200 mg/kg b.w., comparable to or better than a positive drug control (JOINS™, 200 mg/kg) in the cartilage of MIA-OA rats.

Conclusions: Our results demonstrate that ALM16 has a strong chondroprotective effect against the OA model in vitro and in vivo, likely attributed to its anti-inflammatory activity and inhibition of MMP production.

Keywords: Astragalus membranaceus; Lithospermum erythrorhizon; Matrix metalloproteinases (MMPs); Monosodium iodoacetate (MIA); Osteoarthritis (OA).

MeSH terms

  • Analgesics / pharmacology*
  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Astragalus propinquus / chemistry
  • Cartilage, Articular / drug effects*
  • Cartilage, Articular / metabolism
  • Cell Line, Tumor
  • Disease Models, Animal
  • Glycosaminoglycans / analysis
  • Humans
  • Iodoacetic Acid / adverse effects
  • Lithospermum / chemistry
  • Male
  • Matrix Metalloproteinases / analysis
  • Medicine, East Asian Traditional
  • Mice, Inbred ICR
  • Osteoarthritis* / chemically induced
  • Osteoarthritis* / metabolism
  • Osteoarthritis* / physiopathology
  • Plant Extracts / pharmacology*
  • Protective Agents / pharmacology
  • Rats

Substances

  • Analgesics
  • Anti-Inflammatory Agents
  • Glycosaminoglycans
  • Plant Extracts
  • Protective Agents
  • Matrix Metalloproteinases
  • Iodoacetic Acid